TARGETED INTERFERONS DEMONSTRATE POTENT APOPTOTIC AND ANTI-TUMOR ACTIVITIES
First Claim
1. A composition comprising an interferon attached to a targeting moiety that binds to an antigen expressed in or associated with a cell, wherein the targeting moiety is attached to the interferon by a proteolysis resistant peptide linker, wherein the linker comprises at least one amino acid residue.
2 Assignments
0 Petitions
Accused Products
Abstract
Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-α) or interferon beta (IFN-β).
-
Citations
37 Claims
- 1. A composition comprising an interferon attached to a targeting moiety that binds to an antigen expressed in or associated with a cell, wherein the targeting moiety is attached to the interferon by a proteolysis resistant peptide linker, wherein the linker comprises at least one amino acid residue.
-
26. A method for killing or inhibiting the growth or proliferation of a cancer cell, comprising:
-
contacting a cancer cell with an interferon attached to a targeting moiety that binds to a cancer marker expressed in or associated with the cancer cell, wherein the targeting moiety is attached to the interferon by a proteolysis resistant peptide linker, wherein the linker comprises at least one amino acid residue; and killing or inhibiting the growth or proliferation of the cancer cell. - View Dependent Claims (27)
-
-
28. A method for increasing therapeutic efficacy of an interferon for treatment of cancer, comprising:
-
administering to a subject an interferon attached to a targeting moiety that binds to a tumor associated antigen expressed on or associated with a cancer cell in the subject, wherein the targeting moiety is attached to the interferon by a proteolysis resistant peptide linker, wherein the linker comprises at least one amino acid residue; wherein the interferon attached to the targeting moiety is more effective in treating the cancer than the interferon not attached to the targeting moiety. - View Dependent Claims (29)
-
-
30. A method for reducing toxicity associated with administering an interferon to a subject, comprising:
-
administering to a subject an interferon attached to a targeting moiety that binds to a tumor associated antigen expressed in or associated with a cancer cell in the subject, wherein the targeting moiety is attached to the interferon by a proteolysis resistant linker, wherein the linker comprises at least one amino acid residue; wherein administering the interferon attached to the targeting moiety causes less toxicity in the subject than administering the interferon not attached to the targeting moiety. - View Dependent Claims (31)
-
-
32. A method for increasing the in vivo half-life of an interferon upon administration to a subject, comprising:
-
preparing or obtaining a composition comprising an interferon attached to a targeting moiety that binds to an antigen expressed in or associated with a cell, wherein the targeting moiety is attached to the interferon by a proteolysis resistant peptide linker, wherein the linker comprises at least one amino acid residue; identifying a subject that has been previously administered the interferon not attached to the targeting moiety by the linker; and administering to the subject the interferon attached to the targeting moiety by the linker. - View Dependent Claims (33)
-
-
34. A method for treating cancer in a subject resistant to treatment with an antibody, an interferon or both, comprising:
-
identifying a subject with cancer, wherein the subject initially responds to treatment with an antibody, an interferon or both, and wherein the subject subsequently becomes less sensitive to the treatment; administering to the subject a composition comprising the interferon attached to the antibody, wherein the antibody is attached to the interferon by a proteolysis resistant peptide linker, wherein the linker comprises at least one amino acid residue - View Dependent Claims (35, 36)
-
-
37. A method for increasing therapeutic efficacy of an interferon for the treatment of cancer, comprising
preparing or obtaining a composition comprising an interferon attached to a targeting moiety that binds to a tumor associated antigen, wherein the targeting moiety is attached to the interferon by a proteolysis resistant peptide linker, wherein the linker comprises at least one amino acid residue; - and
administering to a subject the interferon attached to the targeting moiety by the linker, wherein the interferon attached to the targeting moiety is more effective in treating cancer in the subject than the interferon not attached to the targeting moiety.
- and
Specification